GERON CORP Increase (Decrease) in Deferred Revenue
GERON CORP (GERN) reported Increase (Decrease) in Deferred Revenue of -$35.00 million for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-03-16
- GERON CORP increase (decrease) in deferred revenue for the quarter ending 2015-12-31 was $0.00.
- GERON CORP increase (decrease) in deferred revenue for fiscal 2015 was -$35.00M, a 200.00% decline from fiscal 2014.
- GERON CORP increase (decrease) in deferred revenue for fiscal 2014 was $35.00M.
- GERON CORP increase (decrease) in deferred revenue for fiscal 2011 was -$350.00K.
- GERON CORP increase (decrease) in deferred revenue for fiscal 2010 was -$700.00K, a 172.09% decline from fiscal 2009.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$35.00M 10-K · filed 2018-03-16 | |
| 2015-09-30 | -$35.00M 10-Q · filed 2016-11-03 | ||
| 2014-12-31 | $35.00M 10-K · filed 2017-03-01 | ||
| 2011-12-31 | -$350.00K 10-K · filed 2014-03-17 | ||
| 2010-12-31 | -$700.00K 10-K · filed 2013-03-15 | ||
| 2009-12-31 | $971.00K 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |